Predicting coronary artery plaque growth using blood flow and cell responses
Tests whether heart scans and blood cell responses can predict plaque growth in adults.
Key facts
- Who runs it
- Queen Mary University of London
- Where
- London, United KingdomSee the site
- Trial code
- Registry title
- Predicting Plaque Growth Using Blood Flow Stress Markers: A Proof-of-Concept Study
- Status
- Recruiting
- People taking part
- 270 people, planned
- Started
- 17 Sept 2026
- Expected to end
- 17 Sept 2031
- Type of study
- Interventional
- Treatments tested
- PCCTA scan
- Endothelial cell isolation from peripheral blood sample
- Record updated
- 7 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 40 or older with stable angina or blocked heart arteries, who are having treatment for coronary artery disease.
- Age
- 40 years or older
- Sex
- All sexes can join.
- Disease stage
- Stable angina with signs of reduced blood flow in a non-invasive test, and/or blocked heart arteries on coronary angiography (more than 70% narrowing of at least one major artery, or a positive fractional flow reserve study).
- Earlier treatment
- No previous coronary artery bypass surgery. No heart transplant.
Main reasons for not taking part
- Acute coronary syndrome within the last 3 months
- Kidney function eGFR below 60ml/min/1.73m²
- Decompensated heart failure, or left ventricular ejection fraction of 30% or less
- Expected life span under 2 years
- Pregnancy
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Age ≥40
- Stable angina, defined as typical symptoms with evidence of reversible ischemia in non-invasive test and/or documented obstructive coronary artery disease on coronary angiography (>70% stenosis of at least one major epicardial coronary artery or positive fractional flow reserve study)
- Patient that is willing and can provide written informed consent
Who cannot take part
- Previous coronary artery bypass surgery
- Patient allergic to contrast or cannot receive treatment with aspirin, heparin, or thienopyridines
- Patient that requires surgical revascularization
- Pregnant women will be excluded. All women of childbearing potential will undergo a pregnancy risk assessment and a urine pregnancy test prior to the 12-month PCCTA scan, in line with standard clinical practice for all PCCTA scans
- Acute coronary syndrome within <3 months
- Flow limiting coronary artery disease in the proximal segments of all the 3 epicardial coronaries
- History of heart transplantation
- Extensive coronary artery disease (i.e., multiple chronic total occlusions) or tortuous coronary anatomy that does not allow assessment of the coronary arteries with intravascular imaging
- Estimated glomerular filtration rate (eGFR) <60ml/min/1.73m²
- Decompensated heart failure, or left ventricular ejection fraction ≤30%
- Anticipated life expectancy <2 years
Where in United Kingdom
- Queen Marys University LondonLondon, United KingdomContact: Paul C EvansTaking people
About the trial
What the trial wants to find out
Coronary artery disease occurs when fatty deposits (plaques) build up inside the arteries that supply blood to the heart. Some plaques remain stable, while others continue to grow or become more likely to rupture, which can lead to a heart attack. Identifying plaques that are at higher risk of progression could help doctors provide earlier and more personalized treatment.
Read full original descriptionShow less
The purpose of this study is to determine whether combining information about blood flow within the coronary arteries with information about a person's biological response to blood flow can improve prediction of plaque growth. Participants undergoing treatment for coronary artery disease will have a specialized heart scan to assess blood flow patterns around plaques in their coronary arteries. Researchers will also collect blood samples to study cells that line blood vessels and investigate how these cells respond to blood flow forces.
The study will follow participants over time to determine whether plaques are more likely to progress in individuals who show a stronger biological response to abnormal blood flow. The findings may help researchers develop new ways to identify patients at higher risk of future heart problems and support the development of more personalized approaches to prevention and treatment of coronary artery disease.
The group in the trial
- Single armOther group
Treatment: PCCTA scan and Endothelial cell isolation from peripheral blood sample
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Plaque Prediction Obtained With Shear Stress Endothelial Metrics: A Proof of Principle Study
- Plain-language title
- Predicting coronary artery plaque growth using blood flow and cell responsesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 7 October 2026